CSIMarket
 
Biomea Fusion Inc   (BMEA)
Other Ticker:  
 
 
Price: $15.7650 $-2.09 -11.681%
Day's High: $17.89 Week Perf: 0.93 %
Day's Low: $ 15.76 30 Day Perf: -9.14 %
Volume (M): 1,465 52 Wk High: $ 43.69
Volume (M$): $ 23,093 52 Wk Avg: $19.68
Open: $17.69 52 Wk Low: $8.13



 Market Capitalization (Millions $) 562
 Shares Outstanding (Millions) 36
 Employees 33
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) 67
 Capital Exp. (TTM) (Millions $) 4

Biomea Fusion Inc
Biomea Fusion Inc is a public pharmaceutical company that focuses on the development and commercialization of transformative therapies for patients with genetically defined cancers. The company was founded in 2013 in Emeryville, California, by Dr. Sandesh Seth, a leading oncologist and biotech executive.

The mission of Biomea Fusion is to harness the power of genomic science to develop precision medicine treatments for patients with cancer. The company has a proprietary drug discovery platform that integrates advanced genomic analytics, bioinformatics, and synthetic biology to identify novel targets and develop therapies that can overcome the limitations of existing treatments.

Biomea Fusion's pipeline includes several innovative drug candidates in development for various cancers, including solid tumors and hematologic malignancies. One of its leading candidates is BMF-219, a selective inhibitor of the fusion protein FGFR3-TACC3, which is being developed for patients with bladder cancer and other solid tumors.

The company is also developing BMF-236, an oral FLT3/AXL dual inhibitor, for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. Biomea Fusion's third clinical-stage asset is BMF-140, a targeted therapy for patients with solid tumors harboring NRG1 gene fusions.

In addition to its clinical programs, Biomea Fusion is actively pursuing preclinical and research activities to develop additional drug candidates for patients with cancer.

The company has a strong leadership team and board of directors with extensive experience in both biotech and pharmaceutical industries. Biomea Fusion has received multiple rounds of funding from venture capital firms and listed on the NASDAQ stock exchange in February 202 With a focus on precision medicine and genomic science, Biomea Fusion is at the forefront of developing transformative therapies for patients with cancer.


   Company Address: 900 Middlefield Road, 4th Floor Redwood City 94063 CA
   Company Phone Number: 980-9099   Stock Exchange / Ticker: NASDAQ BMEA
   BMEA is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Biomea Fusion Sets Bold Goals for 2024 and Showcases Clinical Advances at Prestigious J.P. Morgan Healthcare Conference

Published Tue, Jan 9 2024 4:03 PM UTC



Biomea Fusion, a dynamic clinical-stage biopharmaceutical company, made headlines at the 42nd Annual J.P. Morgan Healthcare Conference with its CEO and Chairman of the Board, Thomas Butler, presenting the company's recent clinical progress and outlining its ambitious corporate milestones for the year 2024. With a focused mission to revolutionize treatment options f...

Clinical Study

Biomea Fusion's Groundbreaking Research Points to a Potential Cure for Type 1 Diabetes

Published Mon, Jan 8 2024 2:01 PM UTC

Combining the forces of cutting-edge research and medical innovation, Biomea Fusion has recently announced a significant milestone in their Phase II clinical trial, COVALENT-112. The study marks the dosing of the first patient with Type 1 Diabetes, using their novel investigational drug, BMF-219. This groundbreaking covalent menin inhibitor holds immense promise in regenerat...

Clinical Study

Biomea Fusion's BMF-219 Shows Promising Results in Durable HbA1c Reduction, Paving the Way for a Diabetes Cure

Published Sat, Dec 9 2023 10:30 PM UTC


In the field of medical advancements, one particular research and development company, Biomea Fusion, is garnering significant attention with their groundbreaking investigational drug, BMF-219. Recently, Biomea Fusion announced a near doubling of the percentage of patients experiencing durable HbA1c reduction in the 200 mg dose cohorts. This news brings a glimmer of hop...

Clinical Study

Biomea Fusion's BMF-219 Shows Promising Results in Improving Glycemic Control and Offers Hope for Diabetes Cure

Published Fri, Dec 8 2023 2:00 PM UTC



Biomea Fusion, a leading biopharmaceutical company, recently presented long-term follow-up data demonstrating improved glycemic control in adults with Type 2 Diabetes after 22 weeks off treatment. This groundbreaking research was shared during a poster presentation at the prestigious World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC). The...

Clinical Study

Biomea Fusion, a leading biopharmaceutical company, is set to present groundbreaking long-term follow-up data from the ongoing Phase II study of BMF-219 at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) The study investigates the potential of BMF-219, an investigational novel covalent menin inhibitor, to regenerate insulin-producing beta cells in adults with Type 2 Diabetes This exciting research holds immense promise for potentially curing diabetes

Published Thu, Dec 7 2023 2:15 PM UTC

Biomea Fusion, a leading biopharmaceutical company, is set to present groundbreaking long-term follow-up data from the ongoing Phase II study of BMF-219 at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC). The study investigates the potential of BMF-219, an investigational novel covalent menin inhibitor, to regenerate insulin-producing beta c...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com